ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Aquestive Therapeutics, Inc. Investors to Secure Counsel Before Important April 30 Deadline in Securities Class Action – AQST

<br /> ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Aquestive Therapeutics, Inc. Investors to Secure Counsel Before Important April 30 Deadline in Securities Class Action – AQST<br />

PR Newswire


NEW YORK

,

April 1, 2021

/PRNewswire/ —

WHY:

Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Aquestive Therapeutics, Inc. (NASDAQ:AQST) between

December 2, 2019

and

September 25, 2020

, inclusive (the “Class Period”), of the important


April 30, 2021

lead plaintiff deadline

.


SO WHAT:

If you purchased Aquestive securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.


WHAT TO DO NEXT:

To join the Aquestive class action, go to

http://www.rosenlegal.com/cases-register-2047.html

or call

Phillip Kim, Esq.

toll-free at 866-767-3653 or email

pkim@rosenlegal.com

or

cases@rosenlegal.com

for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court

no later than

April 30, 2021


. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.


WHY ROSEN LAW:

We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience or resources. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over

$438 million

for investors. In 2020 founding partner

Laurence Rosen

was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.


DETAILS OF THE CASE:

According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) data included in the Libervant Buccal Film for the management of seizure clusters (“Libervant”) New Drug Application (“NDA”) submission showed a lower drug exposure level than desired for certain weight groups; (2) the foregoing significantly decreased the Libervant NDA’s approval prospects; (3) as a result, it was foreseeable that the U.S. Food and Drug Administration would not approve the Libervant NDA in its current form; and (4) as a result, defendants’ public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Aquestive class action, go to

http://www.rosenlegal.com/cases-register-2047.html

or call

Phillip Kim, Esq.

toll-free at 866-767-3653 or email

pkim@rosenlegal.com

or

cases@rosenlegal.com

for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn:

https://www.linkedin.com/company/the-rosen-law-firm

, on Twitter:



or on Facebook:

https://www.facebook.com/rosenlawfirm/

.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:


Laurence Rosen, Esq.



Phillip Kim, Esq.


The Rosen Law Firm, P.A.

275 Madison Avenue, 40th Floor


New York, NY

10016

Tel: (212) 686-1060

Toll Free: (866) 767-3653

Fax: (212) 202-3827


lrosen@rosenlegal.com



pkim@rosenlegal.com



cases@rosenlegal.com



www.rosenlegal.com

Cision
View original content:

http://www.prnewswire.com/news-releases/rosen-top-ranked-investor-counsel-encourages-aquestive-therapeutics-inc-investors-to-secure-counsel-before-important-april-30-deadline-in-securities-class-action–aqst-301261107.html

SOURCE Rosen Law Firm, P.A.